Approximately 10 million men and women in the US have osteoporosis, 1 a metabolic bone
disease characterized by low bone density and deterioration of bone architecture that …

Transitioning postmenopausal women with osteoporosis from a bisphosphonate to
denosumab appears to be safe and more effective at improving BMD than continuing …

Context It is uncertain which osteoporosis therapy is more effective: bisphosphonates or
denosumab. Objective To determine whether denosumab therapy increases bone mineral …

Background The standard treatment for osteoporosis was controversial. Denosumab and
bisphosphonates were two most common drugs. The purpose of this study was to compare …

Abstract Denosumab (Prolia®; Pralia®) is a human monoclonal antibody targeting the key
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …

Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in
postmenopausal women with osteoporosis. In subjects who were treatment-naïve or …

Background Bisphosphonates and denosumab are used extensively in the treatment of
postmenopausal osteoporosis. Despite their proven efficacy in the reduction of vertebral and …

The aim of this review is to compare the efficacy and safety of denosumab over other
treatments for osteoporosis. The results of this study suggest that the safety of denosumab …

The aim of this study was to perform a head‐to‐head comparison of efficacy and safety
profile between 60 mg denosumab (Den) subcutaneously (SC) per 6 months (Q6M) and 70 …

Efficient therapies are available for the treatment of osteoporosis. Anti‐resorptive therapies,
including bisphosphonates and denosumab, increase bone mineral density (BMD) and …